$3.87 Billion is the total value of Rock Springs Capital Management LP's 128 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 6.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HUM | Buy | HUMANA INC | $206,934,000 | +3.7% | 426,500 | +0.0% | 5.34% | -8.0% |
| AGL | Buy | AGILON HEALTH INC | $181,446,000 | +8.2% | 7,747,500 | +0.9% | 4.69% | -4.0% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $163,996,000 | +64.5% | 3,493,743 | +30.8% | 4.24% | +46.0% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $136,108,000 | -1.3% | 269,500 | +0.4% | 3.52% | -12.4% |
| PODD | Buy | INSULET CORP | $118,944,000 | +8.7% | 518,500 | +3.3% | 3.07% | -3.5% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $117,222,000 | +39.4% | 3,262,500 | +19.2% | 3.03% | +23.7% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $101,352,000 | +104.9% | 1,538,195 | +57.1% | 2.62% | +81.9% |
| PEN | Buy | PENUMBRA INC | $90,250,000 | +80.5% | 476,000 | +18.6% | 2.33% | +60.2% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $86,477,000 | +33.2% | 3,057,869 | +4.4% | 2.23% | +18.3% |
| IDXX | Buy | IDEXX LABS INC | $73,082,000 | -6.9% | 224,315 | +0.3% | 1.89% | -17.3% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $70,626,000 | +51.2% | 2,499,148 | +41.4% | 1.82% | +34.1% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $66,062,000 | +29.6% | 845,000 | +12.1% | 1.71% | +15.0% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $62,350,000 | +13.7% | 3,961,249 | +0.9% | 1.61% | +0.9% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $60,536,000 | +6.7% | 866,776 | +2.6% | 1.56% | -5.3% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $52,140,000 | -8.9% | 631,000 | +4.8% | 1.35% | -19.1% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $49,195,000 | -24.6% | 1,187,992 | +8.7% | 1.27% | -33.0% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $47,532,000 | +48.2% | 430,000 | +0.5% | 1.23% | +31.5% |
| AKRO | Buy | AKERO THERAPEUTICS INC | $46,648,000 | +626.5% | 1,369,973 | +101.6% | 1.20% | +544.4% |
| WST | Buy | WEST PHARMACEUTICAL SVSC INC | $44,417,000 | +32.3% | 180,500 | +62.6% | 1.15% | +17.4% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $43,141,000 | +640.7% | 1,760,865 | +25.5% | 1.11% | +559.2% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $41,730,000 | +22.1% | 1,155,961 | +2.9% | 1.08% | +8.3% |
| BAX | Buy | BAXTER INTL INC | $40,691,000 | -9.7% | 755,500 | +7.7% | 1.05% | -19.8% |
| Buy | CINCOR PHARMA INC | $39,576,000 | +105.7% | 1,205,856 | +18.1% | 1.02% | +82.5% | |
| DXCM | Buy | DEXCOM INC | $39,505,000 | +12.1% | 490,500 | +3.7% | 1.02% | -0.6% |
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $38,085,000 | +109.3% | 645,407 | +0.1% | 0.98% | +86.0% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $37,728,000 | +12.9% | 1,795,733 | +4.5% | 0.97% | +0.1% |
| IRTC | Buy | IRHYTHM TECHNOLOGIES INC | $36,738,000 | +26.0% | 293,250 | +8.6% | 0.95% | +11.8% |
| NVRO | Buy | NEVRO CORP | $36,674,000 | +8.2% | 787,000 | +1.8% | 0.95% | -4.0% |
| FRPT | Buy | FRESHPET INC | $35,063,000 | +6.0% | 700,000 | +9.8% | 0.91% | -5.9% |
| PHR | Buy | PHREESIA INC | $33,188,000 | +2.2% | 1,302,500 | +0.3% | 0.86% | -9.3% |
| ABCM | Buy | ABCAM PLCads | $30,467,000 | +30.0% | 2,032,500 | +25.4% | 0.79% | +15.4% |
| ACCD | Buy | ACCOLADE INC | $25,969,000 | +59.5% | 2,274,000 | +3.4% | 0.67% | +41.6% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $22,788,000 | +49.2% | 1,046,743 | +34.9% | 0.59% | +32.4% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $21,578,000 | +39.6% | 1,712,507 | +17.2% | 0.56% | +23.8% |
| CYTK | Buy | CYTOKINETICS INC | $21,463,000 | +36.6% | 443,000 | +10.8% | 0.55% | +21.2% |
| VERV | Buy | VERVE THERAPEUTICS INC | $19,196,000 | +149.2% | 558,837 | +10.9% | 0.50% | +121.4% |
| GOSS | New | GOSSAMER BIO INC | $19,012,000 | – | 1,586,962 | +100.0% | 0.49% | – |
| EXAS | Buy | EXACT SCIENCES CORP | $18,799,000 | -16.7% | 578,600 | +1.0% | 0.49% | -26.0% |
| CNMD | Buy | CONMED CORP | $18,680,000 | -12.5% | 233,000 | +4.5% | 0.48% | -22.4% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $18,379,000 | -6.0% | 450,466 | +26.7% | 0.48% | -16.5% |
| Buy | AURA BIOSCIENCES INC | $18,406,000 | +28.8% | 1,015,757 | +0.7% | 0.48% | +14.2% | |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $17,574,000 | -17.0% | 1,683,358 | +0.1% | 0.45% | -26.3% |
| OLK | Buy | OLINK HLDG ABsponsored ads | $17,542,000 | -6.3% | 1,445,000 | +17.3% | 0.45% | -16.9% |
| Buy | WARBY PARKER INC | $17,468,000 | +21.8% | 1,309,475 | +2.8% | 0.45% | +8.2% | |
| IMTX | Buy | IMMATICS N.V | $16,812,000 | +71.1% | 1,681,224 | +49.0% | 0.43% | +51.7% |
| ANAB | Buy | ANAPTYSBIO INC | $14,709,000 | +26.6% | 576,600 | +0.8% | 0.38% | +12.4% |
| BRKS | Buy | AZENTA INC | $14,152,000 | +21.2% | 330,200 | +103.8% | 0.37% | +7.6% |
| CMPX | Buy | COMPASS THERAPEUTICS INC | $12,160,000 | -13.9% | 5,333,188 | +0.1% | 0.31% | -23.6% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $11,851,000 | +31.0% | 421,604 | +25.7% | 0.31% | +16.3% |
| NVAX | Buy | NOVAVAX INC | $10,907,000 | -55.4% | 599,300 | +26.1% | 0.28% | -60.3% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $9,173,000 | -0.0% | 1,325,625 | +1.0% | 0.24% | -11.2% |
| KNTE | Buy | KINNATE BIOPHARMA INC | $8,926,000 | +14.5% | 746,973 | +20.8% | 0.23% | +1.8% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $8,019,000 | -2.1% | 1,066,408 | +30.8% | 0.21% | -13.0% |
| INZY | Buy | INOZYME PHARMA INC | $7,524,000 | -40.3% | 2,807,618 | +6.3% | 0.19% | -47.0% |
| GMDA | Buy | GAMIDA CELL LTD | $6,551,000 | +70.2% | 4,119,883 | +89.4% | 0.17% | +50.9% |
| MREO | Buy | MEREO BIOPHARMA GROUP PLCspon ads | $5,377,000 | -22.9% | 6,244,897 | +0.2% | 0.14% | -31.5% |
| MGNX | Buy | MACROGENICS INC | $4,175,000 | +48.3% | 1,206,642 | +26.4% | 0.11% | +31.7% |
| LPTX | Buy | LEAP THERAPEUTICS INC | $3,221,000 | -23.3% | 3,659,847 | +0.2% | 0.08% | -32.0% |
| ALT | New | ALTIMMUNE INC | $2,851,000 | – | 223,255 | +100.0% | 0.07% | – |
| Buy | ICOSAVAX INC | $2,468,000 | -43.4% | 781,000 | +2.6% | 0.06% | -49.6% | |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $1,796,000 | +15.7% | 3,413,906 | +11.1% | 0.05% | +2.2% |
| VINC | Buy | VINCERX PHARMA INC | $1,530,000 | +42.3% | 1,108,570 | +36.2% | 0.04% | +29.0% |
| New | BIOHAVEN LTD | $1,055,000 | – | 167,421 | +100.0% | 0.03% | – | |
| ALT | New | ALTIMMUNE INCcall | $428,000 | – | 33,500 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.